Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 88 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $42,618 | -66.4% | 6,249 | -75.9% | 0.00% | -100.0% |
Q4 2022 | $126,714 | -68.9% | 25,966 | -8.1% | 0.00% | -50.0% |
Q3 2022 | $407,000 | +60.9% | 28,251 | +81.4% | 0.00% | 0.0% |
Q4 2021 | $253,000 | -19.7% | 15,577 | +49.3% | 0.00% | -60.0% |
Q1 2021 | $315,000 | -44.3% | 10,433 | -20.4% | 0.01% | -37.5% |
Q2 2020 | $566,000 | +138.8% | 13,111 | +72.8% | 0.01% | +14.3% |
Q4 2019 | $237,000 | – | 7,588 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |